MedTrace Logo

LAM Pilot Study With Imatinib Mesylate

NCT03131999 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-06-16

Study results available
· View outcomes & findings →

Summary

This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).

Conditions

  • Lymphangioleiomyomatosis

Interventions

DRUG

Imatinib Mesylate 400Mg Capsule

Sirolimus or everolimus will be withdrawn after 28 days if used at baseline

DRUG

Placebo - Capsule

Sirolimus or everolimus will be withdrawn after 28 days if used at baseline

Sponsors & Collaborators

Principal Investigators

  • Christopher Meinberg · Congressionally Directed Medical Research Programs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-23
Primary Completion
2019-03-07
Completion
2019-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131999 on ClinicalTrials.gov